Ben Wilkins1, MBChB; Suphot Srimahachota2, MD; Ole De Backer3, MD, PhD; Smonporn Boonyartavej2, MD; Vorarit Lertsuwunseri2, MD; Monravee Tumkosit4, MD; Lars Søndergaard3, MD, DMSc
1. Department of Cardiology, Dunedin Hospital, Dunedin, New Zealand; 2. Cardiac Center and Division of Cardiovascular Disease, Department of Medicine, King Chulalongkorn Memorial Hospital and Chulalongkorn University, Bangkok, Thailand; 3. The Heart Centre, Rigshospitalet, Copenhagen University Hospital, Copenhagen, Denmark; 4. Cardiac Center and Department of Radiology, King Chulalongkorn Memorial Hospital and Chulalongkorn University, Bangkok, Thailand
Several strategies have been devised to obliterate the left atrial appendage (LAA) space, which is the suspected origin of the majority of cardioembolic thrombi in patients with non-valvular atrial fibrillation (NVAF)-related stroke1. The Omega™ LAA occluder (Vascular Innovations Co., Ltd., Nonthaburi, Thailand) is a novel self-expanding, cup-and-disc device made from a continuous, platinum-coated nitinol wire mesh (Figure 1), designed to occlude the LAA. The cup and disc are linked together by a flexible connecting waist. The disc has a polypropylene fabric securely sewn inside it, adding to the occlusive aspect of the device. For stabilisation, the cup ...